Souquet Pierre-Jean, Gerinière Laurence
Hospices civils de Lyon, Centre hospitalier Lyon-Sud, 69495 Pierre-Bénite.
Bull Cancer. 2002 Aug;89 Spec No:S80-4.
Actually gemcitabine is a main drug in the treatment of non small cell lung cancer (NSCLC). The doublet gemcitabine and cisplatin is a standard treatment, widely used in the world. The review of the literature, and specially several recent randomised phase III trial in stage IV NSCLC demonstrates the reproducibility of the results, and a manageable toxicity which allows its use in preoperative setting in stages I, II and resectable III. The carboplatin-gemcitabine doublet is under investigation.
实际上，吉西他滨是治疗非小细胞肺癌（NSCLC）的主要药物。吉西他滨与顺铂的联合用药是一种标准治疗方案，在全球广泛应用。对文献的综述，特别是最近几项针对IV期NSCLC的随机III期试验表明，结果具有可重复性，且毒性可控，这使得其可用于I期、II期和可切除III期的术前治疗。卡铂-吉西他滨联合用药正在研究中。
